Sumary of Pfizer files for use of COVID pill in US:
- Pfizer Inc is seeking US authorisation of its experimental antiviral COVID-19 pill that cut the chance of hospitalisation or death for adults at risk of severe disease by 89 per cent in a clinical trial.
- It is not immediately clear when US regulators will rule on Pfizer’s application.
- “We are moving as quickly as possible in our effort to get this potential treatment into the hands of patients, and we look forward to working with the US FDA on its review of our application, along with other regulatory agencies around the world,” Pfizer Chief Executive Albert Bourla said in a news release.
- A Pfizer spokesman said that the data the company is submitting came from testing the medicine on unvaccinated, high-risk participants.